Note Agreements in the Biotechnology Industry

1,799 Contracts & Agreements

Browse by Company

AbbVie Inc. (8 contracts)
ABEONA THERAPEUTICS INC. (5)
ACADIA PHARMACEUTICALS INC (1)
ACCELERON PHARMA INC (1)
Acorda Therapeutics (5)
Adamas Pharmaceuticals Inc (2)
Adhera Therapeutics, Inc. (30)
ADiTx Therapeutics, Inc. (33)
ADMA BIOLOGICS, INC. (1)
ADURO BIOTECH, INC. (3)
Advaxis, Inc. (30)
AGENUS INC (11)
AgeX Therapeutics, Inc. (14)
Akebia Therapeutics, Inc. (5)
Alexion Pharmaceuticals (2)
Allarity Therapeutics, Inc. (10)
Alliqua BioMedical, Inc. (19)
Alpha Healthcare Acquisition Corp. (1)
Altimmune, Inc. (5)
Alzamend Neuro, Inc. (1)
AMARILLO BIOSCIENCES INC (14)
AMARIN CORP PLC (1)
Amgen Inc. (17)
AMICUS THERAPEUTICS, INC. (10)
AmpliPhi Biosciences Corp (1)
Amplitude Healthcare Acquisition Corp (1)
ANAVEX LIFE SCIENCES CORP. (7)
Aptevo Therapeutics Inc. (1)
AquaBounty Technologies, Inc. (2)
Aridis Pharmaceuticals, Inc. (4)
ARROWHEAD PHARMACEUTICALS, INC. (1)
Artiva Biotherapeutics, Inc. (1)
ARYA Sciences Acquisition Corp II (1)
ASSEMBLY BIOSCIENCES, INC. (4)
ATHERSYS, INC (1)
aTYR PHARMA INC (1)
Avid Bioservices, Inc. (3)
Axcella Health Inc. (1)
AZIYO BIOLOGICS, INC. (3)
AzurRx BioPharma, Inc. (4)
BeiGene, Ltd. (1)
BELLICUM PHARMACEUTICALS, INC (1)
Big Cypress Acquisition Corp. (1)
bioAffinity Technologies, Inc. (8)
BioAtla, Inc. (1)
BioCardia, Inc. (6)
BIOCEPT INC (10)
Biogen Inc. (3)
Biohaven Pharmaceutical Holding Co Ltd. (1)
BioLife4D Corp (18)
BIOMARIN PHARMACEUTICAL INC (6)
BioRestorative Therapies, Inc. (23)
Biostage, Inc. (2)
BIOTIME INC (4)
BioXcel Therapeutics, Inc. (1)
BIOXYTRAN, INC (16)
Bone Biologics Corp (24)
BullFrog AI Holdings, Inc. (2)
CALADRIUS BIOSCIENCES, INC. (3)
Calyxt, Inc. (2)
CANCER GENETICS, INC (12)
CAPRICOR THERAPEUTICS, INC. (3)
CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (7)
Capstone Therapeutics Corp. (6)
CareDx, Inc. (1)
Caribou Biosciences, Inc. (1)
CASI Pharmaceuticals, Inc. (8)
Castle Creek Biosciences, Inc. (1)
CATALYST BIOSCIENCES, INC. (4)
CATALYST PHARMACEUTICALS, INC. (1)
CEL SCI CORP (1)
Celcuity Inc. (1)
Cell Source, Inc. (23)
Celldex Therapeutics, Inc. (2)
Cellectar Biosciences, Inc. (2)
Celsion CORP (1)
Centessa Pharmaceuticals Ltd (3)
CEREBAIN BIOTECH CORP. (18)
Chanticleer Holdings, Inc. (5)
Chardan Healthcare Acquisition 2 Corp. (2)
Chardan Healthcare Acquisition Corp. (2)
Chelsea Worldwide Inc. (3)
CHIMERIX INC (1)
CLEVELAND BIOLABS INC (4)
CM Life Sciences III Inc. (1)
CohBar, Inc. (1)
Coherus BioSciences, Inc. (3)
Comera Life Sciences Holdings, Inc. (1)
Conatus Pharmaceuticals Inc. (3)
Consonance-HFW Acquisition Corp. (1)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (40)
CTD HOLDINGS INC (2)
CTI BIOPHARMA CORP (2)
Curative Biotechnology Inc (15)
CURIS INC (3)
Cyclacel Pharmaceuticals, Inc. (1)
CytoDyn Inc. (21)
CYTORI THERAPEUTICS, INC. (4)
Diffusion Pharmaceuticals Inc. (6)
Digital Development Partners, Inc. (14)
DYADIC INTERNATIONAL INC (4)
Dynamics Special Purpose Corp. (4)
Eidos Therapeutics, Inc. (1)
Emerald Bioscience, Inc. (2)
Emergent BioSolutions Inc. (4)
ENDONOVO THERAPEUTICS, INC. (9)
Enochian Biosciences Inc (9)
Entasis Therapeutics Holdings Inc. (1)
Environmental Impact Acquisition Corp (3)
Esperion Therapeutics, Inc. (1)
Exelixis (6)
FATE THERAPEUTICS INC (4)
FENNEC PHARMACEUTICALS INC. (1)
Fibrocell Science, Inc. (3)
FLUOROPHARMA MEDICAL, INC. (15)
Fortress Biotech, Inc. (6)
FS Development Corp. (1)
FS Development Corp. II (2)
GALECTIN THERAPEUTICS INC (5)
Gamida Cell Ltd. (1)
Gemphire Therapeutics Inc. (2)
Gene Biotherapeutics, Inc. (9)
GENELUX CORP (3)
GENEREX BIOTECHNOLOGY CORP (10)
Genprex, Inc. (3)
GeoVax Labs, Inc. (5)
GERON CORP (4)
Gilead Sciences (8)
Greater Cannabis Company, Inc. (15)
GT Biopharma, Inc. (27)
GX Acquisition Corp. (2)
HALOZYME THERAPEUTICS INC (2)
HARBOR DIVERSIFIED, INC. (2)
HCW Biologics Inc. (2)
Health Sciences Acquisitions Corp (1)
HEAT BIOLOGICS, INC. (3)
HedgePath Pharmaceuticals, Inc. (6)
HEMISPHERX BIOPHARMA INC (8)
HERON THERAPEUTICS, INC. (3)
HilleVax, Inc. (1)
Hillstream BioPharma Inc. (2)
HISTOGENICS CORP (5)
Homology Medicines, Inc. (2)
HUMANIGEN, INC (9)
iBio, Inc. (3)
IDERA PHARMACEUTICALS, INC. (2)
Immix Biopharma, Inc. (1)
IMMUCELL CORP (6)
IMMUNE PHARMACEUTICALS INC (13)
Immune Therapeutics, Inc. (30)
ImmunoCellular Therapeutics, Ltd. (1)
IMMUNOGEN INC (1)
IMPEL NEUROPHARMA INC (1)
Incyte (2)
INFINITY PHARMACEUTICALS, INC. (1)
Inhibikase Therapeutics, Inc. (6)
Inhibrx, Inc. (3)
Innovation Pharmaceuticals Inc. (1)
INOVIO PHARMACEUTICALS, INC. (1)
INSMED Inc (1)
Inspyr Therapeutics, Inc. (1)
INTERCEPT PHARMACEUTICALS, INC. (1)
International Stem Cell CORP (32)
INTREXON CORP (2)
Intrinsic Medicine, Inc. (1)
Invitae Corp (4)
IONIS PHARMACEUTICALS INC (2)
IOVANCE BIOTHERAPEUTICS, INC. (10)
IRONWOOD PHARMACEUTICALS INC (5)
Isoray, Inc. (2)
KalVista Pharmaceuticals, Inc. (2)
KBL MERGER CORP. IV (10)
Kiromic Biopharma, Inc. (22)
KIWA BIO-TECH PRODUCTS GROUP CORP (7)
Kodiak Sciences Inc. (4)
Kura Oncology, Inc. (4)
LA JOLLA PHARMACEUTICAL CO (1)
Leisure Acquisition Corp. (19)
LEXICON PHARMACEUTICALS, INC. (1)
LifeSci Acquisition Corp. (1)
Ligand Pharmaceuticals Incorporated (6)
Locust Walk Acquisition Corp. (2)
LONGEVERON LLC (1)
MADRIGAL PHARMACEUTICALS, INC. (4)
MANHATTAN SCIENTIFICS INC (5)
MANNKIND CORP (16)
MARIZYME INC (30)
Marker Therapeutics, Inc. (4)
MATEON THERAPEUTICS INC (22)
Medovex Corp. (19)
MiMedx Group, Inc. (7)
Minerva Neurosciences, Inc. (14)
MiNK Therapeutics, Inc. (5)
MIRAGEN THERAPEUTICS, INC. (2)
Molecular Templates, Inc. (1)
NANOVIRICIDES, INC. (2)
NantKwest, Inc. (21)
NAVIDEA BIOPHARMACEUTICALS, INC. (9)
NEWLINK GENETICS CORP (4)
NexImmune, Inc. (1)
NORTHWEST BIOTHERAPEUTICS INC (3)
NOVAVAX INC (10)
NTN BUZZTIME INC (7)
Nuo Therapeutics, Inc. (19)
Ohr Pharmaceutical Inc (2)
OncBioMune Pharmaceuticals, Inc (36)
OncoCyte Corp (1)
ONCOSEC MEDICAL Inc (1)
OPGEN INC (17)
Opko Health, Inc. (5)
ORAGENICS INC (23)
Organicell Regenerative Medicine, Inc. (3)
Organogenesis Holdings Inc. (4)
Orgenesis Inc. (12)
Outlook Therapeutics, Inc. (11)
PDL BIOPHARMA, INC. (3)
Petra Acquisition Inc. (5)
PharmaCyte Biotech, Inc. (1)
POLARITYTE, INC. (1)
PRECISION BIOSCIENCES INC (2)
PREDICTIVE TECHNOLOGY GROUP, INC. (1)
PREMIER BIOMEDICAL INC (25)
PROGENITY, INC. (4)
Propanc Biopharma, Inc. (105)
Protagenic Therapeutics, Inc. (20)
Protalix BioTherapeutics, Inc. (7)
PROTEOSTASIS THERAPEUTICS, INC. (1)
ProtoKinetix, Inc. (2)
PTC THERAPEUTICS, INC. (1)
PUMA BIOTECHNOLOGY, INC. (6)
Q BioMed Inc. (3)
Qrons Inc. (5)
Radius Health, Inc. (5)
Rasna Therapeutics Inc. (2)
Regeneron Pharmaceuticals (2)
REGENERX BIOPHARMACEUTICALS INC (14)
Regulus Therapeutics Inc. (1)
RenovaCare, Inc. (5)
RenovoRx, Inc. (3)
Retrophin, Inc. (4)
REXAHN PHARMACEUTICALS, INC. (4)
Rezolute, Inc. (3)
Rich Pharmaceuticals, Inc. (46)
RITTER PHARMACEUTICALS INC (5)
Sarepta Therapeutics, Inc. (1)
SELLAS Life Sciences Group, Inc. (6)
Shuttle Pharmaceuticals Holdings, Inc. (21)
Social Capital Suvretta Holdings Corp. III (2)
SOLENO THERAPEUTICS INC (7)
Sorrento Therapeutics, Inc. (7)
Spectrum Pharmaceuticals, Inc. (1)
SPHERIX INC (3)
Spinning Eagle Acquisition Corp. (1)
Stellar Biotechnologies, Inc. (1)
Summit Therapeutics Inc. (7)
Sun BioPharma, Inc. (4)
SUNESIS PHARMACEUTICALS INC (2)
Sunshine Biopharma, Inc (1)
Syndax Pharmaceuticals Inc (2)
Synthetic Biologics, Inc. (1)
TENAX THERAPEUTICS, INC. (4)
TG THERAPEUTICS, INC. (3)
Tonix Pharmaceuticals Holding Corp. (1)
Trovagene, Inc. (1)
U.S. Stem Cell, Inc. (8)
United Therapeutics Corp (1)
USA EQUITIES CORP. (6)
VACCINEX, INC. (1)
Vertex Pharmaceuticals Inc (2)
Vicapsys Life Sciences, Inc. (1)
Viking Therapeutics, Inc. (1)
VistaGen Therapeutics, Inc. (12)
VITRO DIAGNOSTICS INC (12)
WINDTREE THERAPEUTICS INC (6)
Xenetic Biosciences, Inc. (5)
XOMA Corp (3)
YIELD10 BIOSCIENCE, INC. (2)

Recent Contracts

Form of Senior Secured Promissory Note (VITRO DIAGNOSTICS INC, Filed With SEC on April 17, 2024)
First Amendment to Promissory Note between Immune Therapeutics, Inc. and Ira Gaines dated November 4, 2022 (Immune Therapeutics, Inc., Filed With SEC on April 16, 2024)
Unsecured Promissory Note dated April 10, 2024 (ADiTx Therapeutics, Inc., Filed With SEC on April 12, 2024)
Form of 10% Convertible Note (WINDTREE THERAPEUTICS INC, Filed With SEC on April 8, 2024)
Form of the 25% Senior Secured Convertible Promissory Note (Kiromic Biopharma, Inc., Filed With SEC on April 5, 2024)
Form of Senior Secured Promissory Note, dated March 28, 2024, by and between the Company and the Holder party thereof (HCW Biologics Inc., Filed With SEC on April 1, 2024)
Form of Senior Secured Note Purchase Agreement, dated March 28, 2024, by and between the Company and the Purchaser party thereto (HCW Biologics Inc., Filed With SEC on April 1, 2024)
Agreement with respect to Convertible Notes dated March 26, 2024, among AgeX Therapeutics, Inc., UniverXome Bioengineering, Inc., the Subsidiary Obligors and Juvenescence Limited (AgeX Therapeutics, Inc., Filed With SEC on April 1, 2024)
Allonge and Seventh Amendment to Amended and Restated Convertible Promissory Notes dated March 26, 2024, among AgeX Therapeutics, Inc., the Guarantors party thereto and... (AgeX Therapeutics, Inc., Filed With SEC on April 1, 2024)
8% Convertible Note of Bioxytran, Inc. to Lender in the Principal Amount of $61,500 dated March 15, 2024 (BIOXYTRAN, INC, Filed With SEC on March 22, 2024)
Convertible Promissory Note Purchase Agreement by and between the Registrant and Agenus Inc., dated February 12, 2024 (MiNK Therapeutics, Inc., Filed With SEC on March 21, 2024)
Form of Convertible Promissory Note by and between the Registrant and Agenus Inc., dated February 12, 2024 (MiNK Therapeutics, Inc., Filed With SEC on March 21, 2024)
Amended and Restated Promissory Note between ImmunityBio, Inc. and Nant Capital, LLC dated December 29, 2023 (NantKwest, Inc., Filed With SEC on March 19, 2024)
Letter Amendment dated December 29, 2023 to the Convertible Promissory Notes dated March 31, 2023 (as amended on September 11, 2023) and September 30, 2023 issued by ImmunityBio,... (NantKwest, Inc., Filed With SEC on March 19, 2024)
Senior Convertible Note, dated as of March 14, 2024 (Allarity Therapeutics, Inc., Filed With SEC on March 15, 2024)
Form of convertible promissory note (GX Acquisition Corp., Filed With SEC on March 15, 2024)
Form of Shareholder Note (AzurRx BioPharma, Inc., Filed With SEC on March 14, 2024)
Form of the 25% Senior Secured Convertible Promissory Note (Kiromic Biopharma, Inc., Filed With SEC on March 11, 2024)
Unsecured Promissory Note dated March 7, 2024 (ADiTx Therapeutics, Inc., Filed With SEC on March 11, 2024)
Form of Note Purchase Agreement, dated March 8, 2024, between the Company and the purchaser named therein (PROGENITY, INC., Filed With SEC on March 11, 2024)
Convertible Promissory Note dated March 1, 2024 (Propanc Biopharma, Inc., Filed With SEC on March 11, 2024)
Form of Senior Secured Convertible Promissory Note due March 8, 2027 (DYADIC INTERNATIONAL INC, Filed With SEC on March 11, 2024)
Senior Convertible Promissory Note, dated March 1, 2024, by and between Ayala Pharmaceuticals, Inc. and Israel Biotech Fund I, L.P (Advaxis, Inc., Filed With SEC on March 5, 2024)
Amendment Senior Convertible Notes (Allarity Therapeutics, Inc., Filed With SEC on March 1, 2024)
Form of Unsecured Promissory Note (ADiTx Therapeutics, Inc., Filed With SEC on March 1, 2024)
Form of Amendment No. 4 to January 2024 Secured Notes (ADiTx Therapeutics, Inc., Filed With SEC on February 29, 2024)
Form of 5.500% Note due 2064 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Form of 5.400% Note due 2054 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Form of 5.350% Note due 2044 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Form of 5.050% Note due 2034 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Form of 4.950% Note due 2031 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Form of 4.800 Note due 2029 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Form of 4.800% Note due 2027 (included in Exhibit 4.2 of this Current Report on Form 8-K) (AbbVie Inc., Filed With SEC on February 26, 2024)
Promissory Note dated February 16, 2024, between AIM ImmunoTech Inc. and Streeterville Capital, LLC (HEMISPHERX BIOPHARMA INC, Filed With SEC on February 20, 2024)
Note Purchase Agreement dated February 16, 2024, between AIM ImmunoTech Inc. and Streeterville Capital, LLC (HEMISPHERX BIOPHARMA INC, Filed With SEC on February 20, 2024)
Amended and Restated Promissory Note, dated February 17, 2024, by and (Summit Therapeutics Inc., Filed With SEC on February 20, 2024)
Unsecured Promissory Note dated February 15, 2024 (ADiTx Therapeutics, Inc., Filed With SEC on February 16, 2024)
Senior Convertible Note, dated as of February 13, 2024 (Allarity Therapeutics, Inc., Filed With SEC on February 14, 2024)
Form of the 25% Senior Secured Convertible Promissory Note (Kiromic Biopharma, Inc., Filed With SEC on February 14, 2024)
Sixth Amendment to Amended and Restated Convertible Promissory Note, dated February 9, 2024, between AgeX Therapeutics, Inc. and Juvenescence Limited (AgeX Therapeutics, Inc., Filed With SEC on February 14, 2024)